Описание
Finasteride and tamsulosin are deliberately combined (as Duodart/Jalyn) for BPH treatment; the combination provides additive symptom relief with no significant adverse pharmacokinetic interaction.
Механизм
Finasteride reduces prostatic volume by inhibiting 5-alpha-reductase (reducing dihydrotestosterone), while tamsulosin relaxes prostatic smooth muscle by blocking alpha-1A adrenoceptors. The mechanisms are complementary and pharmacologically independent.
Клиническое значение
MTOPS and CombAT trials confirm superior symptom control with combination vs. monotherapy; no clinically significant adverse interaction. Hypotension is not increased beyond tamsulosin's baseline risk.
Тактика ведения
Standard monitoring for both agents; warn patients about potential first-dose orthostatic hypotension from tamsulosin; monitor PSA (finasteride reduces PSA by ~50% — double observed PSA for interpretation).
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.